Yazarlar : Hendry CE, Little MH.

Yayın : Kidney Int.

Yayın Yılı : 2012

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/22437414

Konu : Rejeneratif Tıp

Literatür İçeriği :  

Abstract

Nuclear reprogramming has reshaped stem cell science and created new avenues for cell-based therapies. The ability to bestow any given phenotype upon adult cells regardless of their origin is an exciting possibility. How can this powerful tool be harnessed for the treatment of kidney disease? Many approaches, including induced pluripotent stem cell (iPSC) production, direct lineage conversion, and reprogramming to a kidney progenitor, are now possible. Indeed, the generation of iPSC lines from adult kidney-derived cells has been successfully achieved. This, however, is just the beginning of the challenge. This review will discuss the fundamental concepts of transcription factor-based reprogramming in its various forms, highlighting recent advances in the field and how these are applicable to the kidney. The relative merits of each approach will be discussed in the context of what is a realistic and feasible strategy for kidney regeneration via reprogramming.Kidney International advance online publication, 21 March 2012; doi:10.1038/ki.2012.68.

Literatür Arşivi

Sunumlar	Videolar	Olgu Tartışması
Incorporating Molecular Data into Risk Stratification for AML	Neden Hematolojiyi seçtim?	Abstract Introduction: Aplastic anemia is a rare disease caused by destruction of pluripotent stem cells in bone marrow. During pregnancy it could be life-threatening for both mother and child. The only causal therapy for aplastic anemia is bone marrow t Novel therapies delay the progression of smoldering multiple myeloma: